Chronic Myeloid Leukemia
The latest news, research, and perspectives in chronic myeloid leukemia (CML). CML is caused by the BCR-ABL1 fusion gene, which is formed by a translocation between chromosomes 9 and 22 (the Philadelphia chromosome), that produces abnormal proteins leading to the development of leukemic cells.
Advertisement
Simona Soverini, PhD, discusses new molecular data on CML, remaining challenges, and potentially practice-changing data.
Countries with a lower sociodemographic index are underrepresented in clinical trials of TKIs for the treatment of CML.
The TKI ponatinib may be the optimal third-line therapy for patients with chronic myeloid leukemia.
Adherence to oral anticancer agents appeared to be good among adults with chronic myeloid leukemia (CML).
Jorge Cortes, MD, discusses the financial toxicity of FDA-approved drugs for malignant hematology and OPTIC trial results.
With a growing number of treatment options, clinicians need guidance on the best third-line options for patients with CML.
Advertisement
The FDA cleared an Investigational New Drug (IND) application for IkT-001Pro for the treatment of chronic myelogenous ...
Blood Cancers Today Associate Editor Jerald Radich, MD, discusses the role of ddPCR for CML in the age of targeted therapies.
SOHO President Moshe Talpaz, MD, shares how it feels to be back onsite for the Annual Meeting.
Of the dozens of posters that were displayed on the first evening of the SOHO Annual Meeting, eight were honored with awards.
International Chronic Myeloid Leukemia (CML) Day takes place on September 22.
Alexandre Bazinet, MD, and colleagues conducted the single-center, dose-expansion phase I/II trial...
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
The phase I/II study will assess the safety and tolerability of the drug.
Researchers shared additional data on the immune response of patients with chronic myeloid leukemia to COVID-19 infection and ...
At least one-quarter of patients experienced arterial occlusive events (AOE), but rates varied depending on the approach.
Researchers surveyed the reasons for low recruitment and early closure of the UK National Cancer Research Institute’s ...
Compared with bosutinib, asciminib was more effective at improving the rate of major molecular response in patients with ...
Downregulation of MS4A3 contributes to disease progression and BCR-ABL inhibitor resistance in chronic-phase CML.
Researchers have discovered that chemotherapy and COVID-19 infection cause neuro-inflammation in similar ways.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726